Company: SWKH
Filing Date: 2025-08-14
Form Type: 10-Q
Source: 0001628280-25-040420
Chunk: 50

Company: SWK Holdings Corp
Filing Date: 2025-08-14
Form: 10-Q
Item: Part I, Item 1
Chunk 50
---
 Receivables and Pharmaceutical Development. These segments reflect the way the Company evaluates its business performance and manages its operations. Please refer to Item 1. Financial Statements, Note 10 of the notes to the unaudited condensed consolidated financial statements for further information regarding segment information.

26

Finance Receivables Portfolio Overview

The table below provides an overview of our outstanding finance receivables transactions as of and for the three and six months ended June 30, 2025 (in thousands, except rate, share and per share data):

Revenue RecognizedRoyalty PurchasesLicensed TechnologyFunded AmountGAAP BalanceQ2 2025Year-to-DateBesivance® (1) Ophthalmic antibiotic$6,000 $— $— $2 Forfivo XL® (6)Depressive disorder treatment6,000 — — 506 Coflex®/Kybella® (6)Spinal stenosis/submental fullness4,350 — — 48 Cambia® (6)NSAID migraine treatment8,500 — — 98 Duo Royalty (6)Japanese Women's health/cystic fibrosis15,353 — — 591 Immune Globulin (6)Immune Globulin Therapeutics 14,100 — — 443 Relief (6)Rare Disease Portfolio7,701 — — 336 Best ABT, Inc.(2), (3)Oncology diagnosis 5,784 2,347 — — Flowonix Medical, Inc.(2), (3), (4)Drug delivery device 12,455 7,133 — — Ideal Implant, Inc.(2), (3)Aesthetics 4,025 2,832 — — Iluvien® (7)Diabetic macular edema16,501 — — 519 Revenue RecognizedTerm LoansTypeMaturity DatePrincipalGAAP BalanceRateQ2 2025Year-to-Date4Web, Inc.First lien07/14/25$19,886 $22,953 12.8%$913 $1,857 AOTI, Inc.First lien02/15/2919,478 19,602 13.0%411 753 Elutia, Inc.First lien08/10/2721,509 25,175